ADRB1 rs1801252: Understanding the Ser49Gly Genetic Variant
The rs1801252 variant is a common genetic change in the ADRB1 gene that results in a Ser49Gly amino acid substitution. It is studied for its potential influence on cardiovascular physiology, including resting heart rate and individual responses to certain blood pressure medications.
What each genotype means
Ser49 homozygous
This genotype results in the Ser49 isoform of the beta-1 adrenergic receptor. Research suggests that individuals with this genotype may experience a more significant decrease in systolic blood pressure when treated with metoprolol compared to those carrying the G allele. Please discuss any medication dosing or response concerns with your clinician or pharmacist.
This is the most common genotype in many populations, though frequency varies significantly by ancestry.
Ser49Gly heterozygous
This genotype results in a mix of Ser49 and Gly49 receptor isoforms. Studies indicate that the Gly49 isoform may demonstrate enhanced agonist-induced downregulation compared to the Ser49 form, which can influence how the body responds to beta-blocker medications. Please discuss any medication dosing or response concerns with your clinician or pharmacist.
This genotype is relatively common, appearing in a significant portion of the population depending on ancestral background.
Gly49 homozygous
This genotype results in the Gly49 isoform of the beta-1 adrenergic receptor, which has been associated with enhanced receptor downregulation in research settings. Because this genotype is rare in many study cohorts, clinical data regarding its specific impact on medication response is limited. Please discuss any medication dosing or response concerns with your clinician or pharmacist.
This genotype is considered rare in many populations, with the G allele frequency typically ranging from 0.12 to 0.25 depending on ancestry.
What is the rs1801252 Variant?
The rs1801252 variant is a single nucleotide polymorphism (SNP) located within the ADRB1 gene. In genetic terms, this variant involves a change from an adenine (A) to a guanine (G) nucleotide. This specific change leads to a missense mutation, meaning it alters the protein sequence by replacing the amino acid serine with glycine at position 49 of the beta-1 adrenergic receptor. Because this receptor is a critical component of the body's signaling system, researchers have long investigated whether this structural change affects how the receptor functions or how it is regulated by the body. It is one of the most frequently studied variants in the ADRB1 gene, often analyzed alongside other nearby variants like rs1801253.
The Role of the ADRB1 Gene
The ADRB1 gene provides instructions for creating the beta-1 adrenergic receptor. This receptor is primarily found in the heart and is a key part of the sympathetic nervous system, which manages the 'fight-or-flight' response. When catecholamines like adrenaline bind to these receptors, they trigger a cascade of signals that increase heart rate, cardiac output, and the force of heart muscle contractions. By regulating these processes, the ADRB1 gene plays a fundamental role in maintaining blood pressure and cardiovascular stability. Because of its central role in heart function, variations in this gene are of significant interest to scientists studying hypertension, heart failure, and the efficacy of beta-blocker medications, which work by inhibiting these very receptors.
Research Associations and Evidence Strength
Research into rs1801252 has yielded mixed results, and the evidence for its clinical impact remains limited. Some studies have explored whether the Gly49 allele influences resting heart rate or the risk of essential hypertension, but findings are often inconsistent across different populations. In the context of pharmacology, there is some evidence suggesting that this variant may influence how patients respond to beta-blocker medications like metoprolol, with some studies indicating that individuals with different genotypes may experience varying degrees of blood pressure reduction. However, these associations are not universally replicated, and the clinical significance is considered modest. It is important to note that many studies are small in scale, and the variant is often analyzed in conjunction with other genetic factors, making it difficult to isolate the specific effect of rs1801252 alone.
What You Can and Cannot Do With This Information
Genetic information regarding rs1801252 is intended for educational purposes and should not be used to make personal health decisions. While research explores potential links to cardiovascular traits or medication response, this variant is not a diagnostic tool for heart disease or a definitive predictor of how you will respond to any specific drug. If you are concerned about your blood pressure, heart rate, or the effectiveness of your current medication, you must consult with your physician or a qualified pharmacist. They can provide guidance based on your full clinical history, lifestyle, and standard medical testing. Never change or stop taking prescribed medications based on genetic test results without professional medical supervision, as doing so could have serious health consequences.
How common is this variant?
The Gly49 (G) allele frequency is approximately 0.12-0.15 in European populations and reaches about 0.25 in populations of African ancestry.
Frequently asked questions
Does the rs1801252 variant cause heart disease?
No, rs1801252 is not a direct cause of heart disease. It is a common genetic variation that may be associated with subtle differences in cardiovascular physiology, but it does not determine whether an individual will develop heart disease.
Can I use this SNP to predict my response to beta-blockers?
While some research suggests this variant might influence how individuals respond to certain medications, the evidence is not strong enough to use it for clinical decision-making. Always discuss your medication response and any concerns with your doctor.
Is the Gly49 allele considered 'bad' for my health?
No, the Gly49 allele is not inherently 'bad.' It is a normal variation found in many healthy individuals across various global populations, and its presence does not imply a health condition.
Should I get tested for the ADRB1 rs1801252 variant?
There is currently no standard medical recommendation to test for this variant. Genetic testing for this SNP is generally not useful for routine clinical care or personal health management.
Sources & further reading
Educational information only, last refreshed 10/15/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1801252?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADRB1
Rare missense variant (Ala187Val) in the beta-1 adrenergic receptor gene ADRB1 that causes familial natural short sleep phenotype via altered adrenergic signaling in sleep-wake circuitry.
A rare missense variant (p.Ala187Val) in the beta-1 adrenergic receptor gene ADRB1 linked to hereditary natural short sleep trait.
A rare variant in the ADRB1 gene linked to the natural short sleep trait in familial studies.
This SNP in the beta-1 adrenergic receptor gene is involved in catecholamine signaling, potentially influencing heart rate response and cardiovascular adaptation to aerobic exercise.